Holen Sie sich die Stockscreener-App
231.54
0.78%
-1.83
Handel nachbörslich:
231.50
-0.04
-0.02%
Schlusskurs vom Vortag:
$233.37
Offen:
$233.57
24-Stunden-Volumen:
336.89K
Relative Volume:
0.79
Marktkapitalisierung:
$9.03B
Einnahmen:
$1.24B
Nettoeinkommen (Verlust:
$42.23M
KGV:
218.43
EPS:
1.06
Netto-Cashflow:
$150.33M
1W Leistung:
-8.67%
1M Leistung:
-8.60%
6M Leistung:
-20.93%
1J Leistung:
+9.58%
1-Tages-Spanne:
$229.95
$236.92
1-Wochen-Bereich:
$228.72
$260.00
52-Wochen-Spanne:
$207.58
$310.00
Penumbra Inc Stock (PEN) Company Profile
Firmenname
Penumbra Inc
Sektor
Branche
Telefon
(510) 995-2486
Adresse
ONE PENUMBRA PLACE, ALAMEDA, CA
Vergleichen Sie PEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
231.54 | 9.10B | 1.24B | 42.23M | 150.33M | 1.06 |
|
ABT
Abbott Laboratories
|
124.67 | 216.57B | 43.84B | 13.94B | 6.78B | 7.9979 |
|
BSX
Boston Scientific Corp
|
100.57 | 148.62B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
368.98 | 141.30B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
90.97 | 117.65B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.48 | 48.55B | 5.69B | 1.41B | 577.90M | 6.9828 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-08 | Hochstufung | Needham | Hold → Buy |
| 2025-09-02 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-14 | Eingeleitet | BofA Securities | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-11 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Eingeleitet | Stifel | Buy |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-31 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-07-31 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-29 | Herabstufung | Needham | Buy → Hold |
| 2023-01-30 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-10-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-09-09 | Hochstufung | Needham | Hold → Buy |
| 2022-07-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-04-19 | Eingeleitet | Deutsche Bank | Buy |
| 2022-03-08 | Eingeleitet | Needham | Hold |
| 2021-09-16 | Eingeleitet | Truist | Buy |
| 2021-06-04 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-10-07 | Fortgesetzt | Canaccord Genuity | Buy |
| 2020-09-29 | Eingeleitet | BTIG Research | Buy |
| 2020-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Eingeleitet | William Blair | Outperform |
| 2018-10-29 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-10-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-02-21 | Eingeleitet | William Blair | Outperform |
| 2018-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-13 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Penumbra Inc Aktie (PEN) Neueste Nachrichten
Is Penumbra Inc. stock undervalued vs historical averages2025 Trade Ideas & Real-Time Volume Analysis Alerts - newser.com
Why Penumbra Inc. stock fits value portfolios2025 Stock Rankings & High Yield Equity Trading Tips - newser.com
Is Penumbra Inc. stock a contrarian opportunityPortfolio Growth Summary & Community Supported Trade Ideas - newser.com
Is Penumbra Inc. stock a top hedge fund pickLong Setup & Weekly Return Optimization Plans - newser.com
Is Penumbra Inc. (0P8) stock a momentum leaderJuly 2025 Technicals & Low Risk Entry Point Guides - newser.com
Is Penumbra’s Stock Still a Good Bet After a 7% Drop in the Past Month? - Yahoo Finance
Custom watchlist performance reports with Penumbra Inc.Entry Point & Verified Short-Term Plans - newser.com
Ischemic Neurological Interventional Medical Devices Market - openPR.com
Penumbra Enters Oversold Territory (PEN) - Nasdaq
Why Penumbra (PEN) Shares Are Falling Today - Yahoo Finance
Truist Financial Sticks to Its Buy Rating for Penumbra (PEN) - The Globe and Mail
How strong dollar benefits Penumbra Inc. stockJuly 2025 Retail & AI Based Buy/Sell Signal Reports - newser.com
Does Penumbra Inc. stock trade at a discount to peersMarket Growth Review & Free Reliable Trade Execution Plans - newser.com
Is Penumbra Inc. (0P8) stock a buy for dividend portfoliosPortfolio Gains Summary & High Accuracy Trade Signal Alerts - newser.com
Why Penumbra Inc. stock is a strong buy callJuly 2025 Action & Daily Profit Focused Stock Screening - newser.com
Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism - Lelezard
Will Penumbra Inc. stock attract ESG investorsJuly 2025 Selloffs & Consistent Income Trade Ideas - newser.com
Penumbra takes TCT by STORM - BioWorld MedTech
Penumbra Inc. Launches i-RISE Study to Enhance Stroke Treatment Insights - TipRanks
Is Penumbra Inc. (0P8) stock among top earnings playsJuly 2025 Update & Reliable Entry Point Trade Alerts - Fundação Cultural do Pará
Penumbra Inc.’s STRIKE-PE Study: A Game Changer for Pulmonary Embolism Treatment? - TipRanks
Penumbra, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape - Markets Mojo
Penumbra Inc.’s STRIDE II Study: A Promising Update for Investors - TipRanks
Penumbra Inc.’s BOLT Study: A Game-Changer for Deep Vein Thrombosis Treatment? - TipRanks
Penumbra study backs mechanical thrombectomy for treating pulmonary embolism - MassDevice
Penumbra (PEN) Trial Shows Superior Results with Mechanical Thro - GuruFocus
Penumbra’s thrombectomy system shows superior results for PE patients - Investing.com
Penumbra’s thrombectomy system shows superior results for PE patients By Investing.com - Investing.com Nigeria
Penumbra (NYSE: PEN) RCT: CAVT 78.3% positive effect vs 51.9% with anticoagulation - Stock Titan
Deep Dive Into Penumbra Stock: Analyst Perspectives (13 Ratings) - Benzinga
Penumbra (PEN) Maintains Buy Rating with $326 Price Target by Ne - GuruFocus
PEN: BTIG Reiterates Buy Rating with $320 Price Target | PEN Sto - GuruFocus
Why Penumbra Inc. (0P8) stock is a strong buy callWeekly Stock Report & Consistent Return Investment Signals - newser.com
Finanzdaten der Penumbra Inc-Aktie (PEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.33%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):